President Donald Trump has declared that generic drugs imported into the U.S. will not incur tariffs for the next two years, starting August 1, 2026. After this grace period, a 100% tariff will be imposed in August 2028, escalating to 200% in 2029. This phased approach is designed to encourage generic drug manufacturers to establish production facilities within the U.S.
Trump characterized the future tariffs as a 'penalty' for companies that fail to relocate their operations domestically. In contrast, tariffs on patented and branded drugs will remain unchanged. Previously, on April 2, Trump enacted a 100% tariff on patented pharmaceutical products and ingredients, while exempting generics and biosimilars.
Major drug companies, including Eli Lilly, Pfizer, and Novo Nordisk, have negotiated agreements with Trump to reduce drug prices, which are part of his 'most favored nation' policy that aligns U.S. drug prices with those in other high-income countries. This policy also exempts these companies from tariffs for three years.
The implications of these tariffs are particularly significant for India, which supplies nearly 50% of the generic medicines consumed in the U.S., with the U.S. representing about a third of India's pharmaceutical exports. Additionally, Chinese firms dominate the supply of active pharmaceutical ingredients, which could be affected by these tariff changes